Maiden Biosciences Inc v. MPM Medical Inc

CourtDistrict Court, N.D. Texas
DecidedMarch 18, 2021
Docket3:18-cv-01354
StatusUnknown

This text of Maiden Biosciences Inc v. MPM Medical Inc (Maiden Biosciences Inc v. MPM Medical Inc) is published on Counsel Stack Legal Research, covering District Court, N.D. Texas primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Maiden Biosciences Inc v. MPM Medical Inc, (N.D. Tex. 2021).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF TEXAS DALLAS DIVISION MAIDEN BIOSCIENCES, INC., § § Plaintiff, § § Civil Action No. 3:18-CV-1354-D VS. § § MPM MEDICAL INC., et al., § § Defendants. § MEMORANDUM OPINION AND ORDER Plaintiff Maiden Biosciences, Inc. (“Maiden”) applies pursuant to Tex. Civ. Prac. & Rem. Code Ann. § 31.002 (West 2019)—the Texas turnover statute—to compel intervenors HWH World, Inc. (“HWH”) and Decentralized Sharing Systems, Inc. (“Decentralized”) to turn over various assets that they allegedly acquired from the defendants in this case in a fraudulent scheme to help defendants avoid creditors. The court denies the application because the court lacks the authority to decide a substantive issue (whether intervenors’ claims to ownership of the assets are invalid) that must be resolved in order to grant the relief Maiden requests. I In 2017 Maiden sued defendants MPM Medical Inc., n/k/a Crown Medical Products, Inc. (“Crown”) and RBC Life Sciences, Inc. (“RBC”) (collectively, “defendants” or the “Judgment Debtors”) for breach of contract and unjust enrichment. In October 2019 RBC entered into a secured convertible note with Decentralized in the amount of $200,000 (the “First Note”). The First Note was secured by a security agreement and a guaranty made by RBC Life Sciences USA, Inc. (“RBC USA”), a wholly owned subsidiary of RBC. The security agreement granted Decentralized a security interest

in all of RBC’s and RBC USA’s assets and personal property, including intellectual property, now or hereafter existing. Decentralized filed an amended UCC financing statement in October 2019. In November 2019 RBC entered into a secured revolving convertible note with HWH1

in the amount of $800,000 (the “Second Note”). The Second Note was secured by a security agreement and a guaranty made by certain RBC subsidiaries (the “RBC Subsidiaries”). Like the first security agreement, the second security agreement granted HWH a security interest in all of RBC’s and the RBC Subsidiaries’ assets and personal property, including intellectual property, now or hereafter existing. HWH filed a UCC financing statement in November

2019. In December 2019 the Judgment Debtors filed an unopposed motion to withdraw their answers and counterclaim and to permit their counsel to withdraw. The court granted the motion on the same day. In January 2020 Decentralized notified RBC USA that it was in default on its

obligations as guarantor of the First Note. Decentralized proposed to grant RBC USA a credit against the First Note in the amount of $115,000 in exchange for collateral. In

1At that time, HWH was known as Bliss International, Inc. - 2 - February 2020 RBC USA accepted Decentralized’s proposal. Pursuant to this acceptance of collateral, Decentralized purports to rightfully own all of RBC USA’s assets. Decentralized does not, however, claim stock ownership in RBC USA.

In February 2020 HWH notified RBC and the RBC Subsidiaries that they were in default on their obligations under the Second Note. HWH proposed to grant RBC and the RBC Subsidiaries a credit against the Second Note in the amount of $100,000 in exchange for collateral. In March 2020 RBC and the RBC Subsidiaries accepted HWH’s proposal.

On the same day, Blue Elephant Financing LLC, then a secured creditor of RBC, objected to this acceptance of collateral, so HWH conducted a public foreclosure sale. HWH contends that it acquired essentially all of RBC’s assets2 in exchange for providing RBC a $150,000 credit against the Second Note at the foreclosure sale in April 2020. On March 2, 2020 this court entered a final default judgment against the Judgment Debtors.3 Maiden then commenced efforts to collect the judgment.

In June 2020 the court granted Maiden’s first application for turnover relief (the “First Turnover Order”) and appointed a receiver (“Receiver”).4 The First Turnover Order 2HWH does not claim stock ownership in certain subsidiaries (RBC USA, Crown, PT Arbici Indonesia, and RBC Life Asia Pacific Corporation). 3The judgment imposed joint and several liability on the Judgment Debtors in the principal sum of $4,329,000, together with prejudgment interest at the rate of 5.00% per annum, attorney’s fees and costs in the sum of $80,109.50, and post-judgment interest at the maximum allowable rate. 4The court granted the application for the First Turnover Order after no response was filed. Neither the Judgment Debtors nor intervenors have sought relief from, or reconsideration of, that order. - 3 - instructed RBC, inter alia, to take all measures reasonably necessary to effectuate the transfer, conveyance, and turnover of the patent and trademarks that it owns. A few months later, the court granted Maiden’s supplemental application for turnover relief. This

supplemental order granted the Receiver the authority to execute an assignment and all other documents reasonably necessary to effectuate the transfer, conveyance, assignment, and turnover of the intellectual property. In September 2020 the court granted Maiden’s second application for turnover relief

(the “Second Turnover Order”). The Second Turnover Order, inter alia, instructed RBC to effectuate the transfer, conveyance, assignment, and turnover of its subsidiary RBC USA to Receiver. In October 2020 Maiden filed a third application for turnover relief (the “Third Application”). The Third Application asked the court to (1) order RBC to turn over its

shares, stocks, and ownership interests in Arlington Laboratories, Inc., a wholly owned subsidiary of RBC; (2) order RBC to turn over all assets identified as collateral in the security agreements; (3) order RBC and Crown to turn over all documents related to their nonexempt property; (4) order intervenors not to interfere with property in the Receiver’s control or otherwise subject to the order; (5) grant Maiden reasonable attorney’s fees and

costs associated with the Third Application; and (6) grant Maiden any other relief that it was justly entitled to receive. While the Third Application was pending, intervenors filed on November 2, 2020 a motion to intervene, seeking to protect their purported assets. On November 17, 2020—like - 4 - the prior applications, in the absence of a response—the court granted Maiden’s Third Application (the “Third Turnover Order”). On December 7, 2020 the court then granted intervenors’ motion to intervene, but it denied their request to file a response to Maiden’s

already-granted Third Application, without prejudice to intervenors’ seeking other available relief. On the same day, intervenors filed a motion for relief from the Third Turnover Order, or, alternatively, for reconsideration. After expedited briefing, the court granted intervenors’ motion for relief and vacated the Third Turnover Order, concluding, at a minimum, that

intervenors had not been afforded due process before the court granted Maiden’s Third Application. The court advised the parties that it would consider Maiden’s Third Application anew, and it permitted the parties to submit supplemental briefs. In December 2020 Maiden filed the instant supplemental third application for turnover relief (“Supplemental Third Application”) that revised the relief Maiden seeks.5 In its

Supplemental Third Application, Maiden requests that the court (1) order intervenors to turn over all assets identified as collateral in the security agreements; (2) order intervenors to turn over all documents related to the assets identified in the security agreements; (3) grant Maiden reasonable attorney’s fees and costs associated with the Supplemental Third Application; and (4) grant Maiden any other relief that it is justly entitled to receive.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Resolution Trust Corp. v. Smith
53 F.3d 72 (Fifth Circuit, 1995)
Maiz v. Virani
311 F.3d 334 (Fifth Circuit, 2002)
In Re Hamel
180 S.W.3d 226 (Court of Appeals of Texas, 2005)
Beaumont Bank, N.A. v. Buller
806 S.W.2d 223 (Texas Supreme Court, 1991)
Black v. Shor
443 S.W.3d 170 (Court of Appeals of Texas, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Maiden Biosciences Inc v. MPM Medical Inc, Counsel Stack Legal Research, https://law.counselstack.com/opinion/maiden-biosciences-inc-v-mpm-medical-inc-txnd-2021.